Related references
Note: Only part of the references are listed.Metformin Protects Endothelial Function in Diet-Induced Obese Mice by Inhibition of Endoplasmic Reticulum Stress Through 5' Adenosine Monophosphate-Activated Protein Kinase-Peroxisome Proliferator-Activated Receptor δ Pathway
Wai San Cheang et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2014)
Peroxisome Proliferator-Activated Receptor δ Agonist GW1516 Attenuates Diet-Induced Aortic Inflammation, Insulin Resistance, and Atherosclerosis in Low-Density Lipoprotein Receptor Knockout Mice
Lazar A. Bojic et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2014)
In Silico Identification of Potent PPAR-γ Agonists from Traditional Chinese Medicine: A Bioactivity Prediction, Virtual Screening, and Molecular Dynamics Study
Kuan-Chung Chen et al.
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE (2014)
The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands
Adam J. Pawson et al.
NUCLEIC ACIDS RESEARCH (2014)
Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: Rationale and design of the AleCardio trial
A. Michael Lincoff et al.
AMERICAN HEART JOURNAL (2013)
Results of a reevaluation of cardiovascular outcomes in the RECORD trial
Kenneth W. Mahaffey et al.
AMERICAN HEART JOURNAL (2013)
Fenofibrate Inhibits Endothelin-1 Expression by Peroxisome Proliferator-Activated Receptor α-Dependent and Independent Mechanisms in Human Endothelial Cells
Corine Glineur et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2013)
Honokiol: A non-adipogenic PPARγ agonist from nature
Atanas G. Atanasov et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2013)
THE CONCISE GUIDE TO PHARMACOLOGY 2013/14: NUCLEAR HORMONE RECEPTORS
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
THE CONCISE GUIDE TO PHARMACOLOGY 2013/14: ENZYMES
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
THE CONCISE GUIDE TO PHARMACOLOGY 2013/14: G PROTEIN-COUPLED RECEPTORS
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Protective role of vascular smooth muscle cell PPARγ in angiotensin II-induced vascular disease
Chiara Marchesi et al.
CARDIOVASCULAR RESEARCH (2013)
Effects of peroxisome proliferator-activated receptor- activation in endothelin-dependent hypertension
Maria Jose Zarzuelo et al.
CARDIOVASCULAR RESEARCH (2013)
Coronary Flow Velocity Reserve is Improved by PPAR- Agonist Fenofibrate in Patients with Hypertriglyceridemia
Guang Wang et al.
CARDIOVASCULAR THERAPEUTICS (2013)
PPAR-γ agonist pioglitazone prevents apoptosis of endothelial progenitor cells from rat bone marrow
Hui-Feng Zhang et al.
CELL BIOLOGY INTERNATIONAL (2013)
Comparing Pioglitazone to Insulin with Respect to Cancer, Cardiovascular and Bone Fracture Endpoints, Using Propensity Score Weights
Carlos Vallarino et al.
CLINICAL DRUG INVESTIGATION (2013)
Therapeutic Effects of PPARα Agonists on Diabetic Retinopathy in Type 1 Diabetes Models
Ying Chen et al.
DIABETES (2013)
The Peroxisome Proliferator Activated Receptor-γ Pioglitazone Improves Vascular Function and Decreases Disease Activity in Patients With Rheumatoid Arthritis
Wendy Marder et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2013)
Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia
Yun-Jung Choi et al.
ATHEROSCLEROSIS (2012)
Cullin-3 Regulates Vascular Smooth Muscle Function and Arterial Blood Pressure via PPARγ and RhoA/Rho-Kinase
Christopher J. Pelham et al.
CELL METABOLISM (2012)
Loss of Perivascular Adipose Tissue on Peroxisome Proliferator-Activated Receptor-γ Deletion in Smooth Muscle Cells Impairs Intravascular Thermoregulation and Enhances Atherosclerosis
Lin Chang et al.
CIRCULATION (2012)
PPARδ Activation Protects Endothelial Function in Diabetic Mice
Xiao Yu Tian et al.
DIABETES (2012)
Activation of peroxisome proliferator-activated receptor-β/-δ (PPARβ/δ) prevents endothelial dysfunction in type 1 diabetic rats
Ana Maria Quintela et al.
FREE RADICAL BIOLOGY AND MEDICINE (2012)
Peroxisome Proliferator-Activated Receptor-γ Ameliorates Pulmonary Arterial Hypertension by Inhibiting 5-Hydroxytryptamine 2B Receptor
Yahan Liu et al.
HYPERTENSION (2012)
Three-in-one agonists for PPAR-α, PPAR-γ, and PPAR-δ from traditional Chinese medicine
Kuan-Chung Chen et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2012)
The nuclear hormone receptor PPARγ counteracts vascular calcification by inhibiting Wnt5a signalling in vascular smooth muscle cells
Estelle Woldt et al.
NATURE COMMUNICATIONS (2012)
Telmisartan inhibits vasoconstriction via PPARγ-dependent expression and activation of endothelial nitric oxide synthase
Chi Yung Yuen et al.
CARDIOVASCULAR RESEARCH (2011)
Adiponectin Is Required for PPARγ-Mediated Improvement of Endothelial Function in Diabetic Mice
Wing Tak Wong et al.
CELL METABOLISM (2011)
The PPAR-RXR Transcriptional Complex in the Vasculature Energy in the Balance
Jorge Plutzky
CIRCULATION RESEARCH (2011)
Effects of the New Dual PPARα/δ Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism
Bertrand Cariou et al.
DIABETES CARE (2011)
Antihypertensive Effects of Peroxisome Proliferator-Activated Receptor-β Activation in Spontaneously Hypertensive Rats
Maria Jose Zarzuelo et al.
HYPERTENSION (2011)
Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation
Jang Hyun Choi et al.
NATURE (2011)
Rosiglitazone Attenuates Endothelin-1-Induced Vasoconstriction by Upregulating Endothelial Expression of Endothelin B Receptor
Jianwei Tian et al.
HYPERTENSION (2010)
Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or Pioglitazone
David J. Graham et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Endothelium-Dependent Vasodilator Effects of Peroxisome Proliferator-Activated Receptor β Agonists via the Phosphatidyl-Inositol-3 Kinase-Akt Pathway
Rosario Jimenez et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
PPAR gamma 1-Induced Caveolin-1 Enhances Cholesterol Efflux and Attenuates Atherosclerosis in Apolipoprotein E-Deficient Mice
Qin Hu et al.
JOURNAL OF VASCULAR RESEARCH (2010)
The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus.
Lukasz Januszkiewicz
KARDIOLOGIA POLSKA (2010)
Induction of Metastatic Gastric Cancer by Peroxisome Proliferator-Activated Receptor delta Activation
Claire B. Pollock et al.
PPAR RESEARCH (2010)
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
Henry N. Ginsberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Pioglitazone enhances collateral blood flow in ischemic hindlimb of diabetic mice through an Akt-dependent VEGF-mediated mechanism, regardless of PPARγ stimulation
Federico Biscetti et al.
CARDIOVASCULAR DIABETOLOGY (2009)
Vascular Smooth Muscle Cell-Selective Peroxisome Proliferator-Activated Receptor-γ Deletion Leads to Hypotension
Lin Chang et al.
CIRCULATION (2009)
Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
Russell Scott et al.
DIABETES CARE (2009)
Separation, Characterization and Dose-Effect Relationship of the PPARγ-Activating Bio-Active Constituents in the Chinese Herb Formulation 'San-Ao Decoction'
Ling Zhou et al.
MOLECULES (2009)
Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: Results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10)
Robert Wilcox et al.
AMERICAN HEART JOURNAL (2008)
Role of inflammation and oxidative stress in endothelial progenitor cell function and mobilization: Therapeutic implications for cardiovascular diseases
Dimitris Tousoulis et al.
ATHEROSCLEROSIS (2008)
Pioglitazone ameliorates endothelial dysfunction and restores ischemia-induced angiogenesis in diabetic mice
Po-Hsun Huang et al.
BIOMEDICINE & PHARMACOTHERAPY (2008)
Fibrate Therapy An Update
Joshua Remick et al.
CARDIOLOGY IN REVIEW (2008)
Interference with PPARγ function in smooth muscle causes vascular dysfunction and hypertension
Carmen M. Halabi et al.
CELL METABOLISM (2008)
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes -: The PERISCOPE randomized controlled trial
Steven E. Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial
Bela F. Asztalos et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2008)
PPARδ regulates multiple proinflammatory pathways to suppress atherosclerosis
Grant D. Barish et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
PPARα:: Mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators
Frank J. Gonzalez et al.
TOXICOLOGY (2008)
Increase in weight induced by muraglitazar, a dual PPARα/γ agonist, in db/db mice:: adipogenesis/or oedema?
S. Mittra et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
Absence of peroxisome proliferator-activated receptor-γ abolishes hypertension and attenuates atherosclerosis in the Tsukuba hypertensive mouse
Karen M. Tordjman et al.
HYPERTENSION (2007)
Increased atherosclerosis following treatment with a dual PPAR agonist in the ApoE knockout mouse
Anna C. Calkin et al.
ATHEROSCLEROSIS (2007)
Macrophage expression of peroxisome proliferator-activated receptor-α reduces atherosclerosis in low-density lipoprotein receptor-deficient mice
Vladimir R. Babaev et al.
CIRCULATION (2007)
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus - A meta-analysis of randomized trials
A. Michael Lincoff et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Effects of thiazolidinediones on blood pressure
Thomas D. Giles et al.
CURRENT HYPERTENSION REPORTS (2007)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
PPARα and PPARγ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome
Catherine Fievet et al.
CURRENT OPINION IN PHARMACOLOGY (2006)
Dual PPARα/γ agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice
A. Susanne M. Zadelaar et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Troglitazone inhibits endothelial cell proliferation through suppression of casein kinase 2 activity
Kuy-Sook Lee et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Peroxisome proliferator-activated receptor-γ-agonist, rosiglitazone, promotes angiogenesis after focal cerebral ischemia
Kon Chu et al.
BRAIN RESEARCH (2006)
Gemfibrozil in the treatment of dyslipidemia -: An 18-year mortality follow-up of the Helsinki Heart Study
L Tenkanen et al.
ARCHIVES OF INTERNAL MEDICINE (2006)
Peroxisome proliferator-activated receptor-α selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice
Rai Ajit K. Srivastava et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2006)
PPARδ regulates glucose metabolism and insulin sensitivity
CH Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Peroxisome proliferator-activated receptor-γ activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors
U Campia et al.
CIRCULATION (2006)
Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients
A Tenenbaum et al.
EUROPEAN HEART JOURNAL (2005)
Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome
A Tenenbaum et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-δ accelerates intestinal adenoma growth
RA Gupta et al.
NATURE MEDICINE (2004)
Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone -: Evidence for involvement of peroxisome proliferator-activated receptor (PPAR)γ-dependent and PPARγ-independent signaling pathways
DH Cho et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease
A Tenenbaum et al.
CIRCULATION (2004)
Transcriptional repression of atherogenic inflammation:: Modulation by PPARδ
CH Lee et al.
SCIENCE (2003)
Ragaglitazar:: a novel PPARα & PPARδ agonist with potent lipidlowering and insulin-sensitizing efficacy in animal models
R Chakrabarti et al.
BRITISH JOURNAL OF PHARMACOLOGY (2003)
Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity
YX Wang et al.
CELL (2003)
Bezafibrate induces a mitochondrial derangement in human cell lines: A PPAR-independent mechanism for a peroxisome proliferator
R Scatena et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2003)
Reduction of atherosclerosis by the peroxisome proliferator-activated receptor α agonist fenofibrate in mice
H Duez et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Regulation of the interleukin-1 receptor antagonist in THP-1 cells by ligands of the peroxisome proliferator-activated receptor γ
CA Meier et al.
CYTOKINE (2002)
Peroxisome proliferator-activated receptor α,γ coagonist LY465608 inhibits macrophage activation and atherosclerosis in apolipoprotein E knockout mice
SH Zuckerman et al.
LIPIDS (2002)
PPARγ:: a nuclear regulator of metabolism, differentiation, and cell growth
ED Rosen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice - Pleiotropic effects on CD36 expression and HDL
Z Chen et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2001)
Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor
T Claudel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Induction of IκBα expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-α activators
P Delerive et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells
T Okura et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2000)
Share Paper
